SYMBIOTEC share price, P/E, ROE & financials

Symbiotec Pharmalab (SYMBIOTEC) had a P/E of 103.5× on 6 Nov 2026, above the industry P/E of 37.3×, and the shares are close to their 52-week high. Sales and net profit grew 17% and 67% a year over 3 years, with ROCE of 14% and ROE of 11%. Debt is 0.34× equity. It is a small-cap company with a market cap of ₹9,727 Cr, ranked 6th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 38% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1,320.00
Day high: ₹1,525.80
Day low: ₹1,320.00
Prev. close: ₹1,271.50
Volume: 75.4 L

Health check

2 good · 1 fair · 3 to check

ReturnsIn line
+37.9% over a year, better than 4 of 7 peers.
Price tagPricier
P/E 103.5 vs industry 37.3.
GrowthStrong
Sales +16.8%, profit +67.3% a year over 3 years.
ProfitabilityWeak
ROCE 14.3% vs peer median 23.6%.
Balance sheetSolid
Debt 0.34× equity, interest covered 7.1×, Piotroski 6 of 9.
Red flags2 to check
Quarterly profit down 53.0% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - General

14 listed peers. Screen the industry

Small cap

₹9,727 Cr, #6 of 15 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹884 Cr · profit ₹94 Cr

Market cap: ₹9,727 Cr; Small cap
P/E: 103.5; Industry 37.3
Price to book: 8.26; Peers 18.55
Dividend yield: 0.00%
ROE: 11.2%; Peers 28.3%
ROCE: 14.3%; Peers 23.6%
Debt to equity: 0.34; Debt ₹391 Cr
EPS (TTM): ₹14.63; Face value ₹2
OPM (TTM): 10.7%; Net margin 10.6%
Sales growth: +7.4%; Latest quarter vs a year ago
Profit growth: −53.0%; Latest quarter vs a year ago
Price to sales: 11.00; EV/EBITDA 45.4

Strengths

Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly profit down 53.0% on a year ago.
P/E of 103.5 against an industry P/E of 37.3.

Derived automatically from reported figures. Not a recommendation.

About Symbiotec Pharmalab

Symbiotec Pharmalab Limited develops, manufactures, and markets active pharmaceutical ingredients (APIs) in India. The company provides cortico-steroid and hormone (Steroid) APIs; nutraceuticals; and other services. The company was founded in 1995 and is based in Indore, India.

Headquarters: Indore
Employees: 1,915
Sector: Healthcare
ISIN: INE899I01028
Website: symbiotec.com

Price range

52 weeks

₹934.20₹1,525.80

Today

₹1,320.00₹1,525.80

Avg volume (3M): 20.8 L
1-year return: plus 37.9%
From 52-week high: minus 0.8%

Peers · Drug Manufacturers - General

Compare with peers Screen the whole industry

Company
GLAXOGlaxosmithkline Pharmaceuticals	2,524.80	plus 0.98%	42,772	37.3	22.73	55.4%	63.9%	34.1%	5.7%	19.3%	2.26%	minus 6.0%
RUBICONRubicon Research	1,659.30	minus 4.67%	27,468	95.6	19.38	23.6%	19.1%	23.3%	–	–	0.09%	plus 166.7%
PFIZERPfizer	3,856.00	minus 0.02%	17,640	23.2	4.02	22.9%	20.9%	36.7%	1.3%	5.0%	1.94%	minus 24.6%
CORONACORONA Remedies	2,441.10	plus 2.58%	14,930	72.1	18.55	29.0%	28.3%	21.3%	16.6%	29.7%	0.41%	plus 69.7%
MARKSANSMarksans Pharma	303.70	minus 3.20%	13,764	24.6	4.13	17.5%	15.2%	22.5%	16.7%	16.2%	0.30%	plus 68.0%
SYMBIOTECSymbiotec Pharmalab	1,513.60	plus 19.04%	9,726	103.5	8.26	14.3%	11.2%	10.7%	16.8%	67.3%	0.00%	plus 37.9%
SANOFICONRSanofi Consumer Healthcare India	3,420.20	minus 0.69%	7,888	28.2	22.64	–	80.4%	37.8%	–	–	2.19%	minus 29.5%
SANOFISanofi India	3,283.10	minus 2.75%	7,561	20.7	9.15	–	44.1%	28.0%	–	–	3.75%	minus 28.9%
Median of 7 peers	–	−0.69%	14,930	28.2	18.55	23.6%	28.3%	28.0%	11.1%	17.7%	1.94%	−6.0%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

₹ Cr	Jun 25	Jun 26
	203	218
	145	173
	58	45.2
	28.5%	20.7%
	2.6	0.3
	5.3	6.2
	10.5	21.8
	44.8	17.5
	33.2%	19.8%
	29.9	14.1
	4.66	2.19

Sep 25, Dec 25, Mar 26 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +16.8%
Profit CAGR 3Y: +67.3%
EPS CAGR 3Y: +67.3%
ROE: 11.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
546	716	752	869
–	+31.2%	+4.9%	+15.6%
473	545	550	631
72.7	171	202	238
13.3%	23.9%	26.9%	27.4%
−1.4	5.7	4.3	3.1
5.4	7.2	16	25.3
28.5	38.8	43.1	53.3
0.8	–	–	−9
38.3	131	147	153
38.6%	23.6%	34.1%	28.3%
23.5	100	96.8	110
–	+326.8%	minus 3.4%	+13.5%
3.65	15.59	15.06	17.10

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
10.9	10.9	10.9	12.5
611	704	804	1,137
220	251	544	391
148	329	220	240
990	1,295	1,580	1,781
577	620	970	1,149
278	208	568	64.5
–	5	6.6	13.4
6.8	25.2	42.3	37.4
128	437	−7.1	517
990	1,295	1,580	1,781

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
69.2	188	47.3	175
−220	−206	−307	−227
146	21.8	278	36
−4.6	2.9	18.9	−16.4
−224	−210	−308	−226
−155	−22.3	−261	−51.1

Shareholding pattern

Source: NSE filings

33.3%

promoters

Promoters33.28%
Public66.72%
As of 30 Sep 2026

Quarter	Split	Promoters	Public	Promoter change
30 Sep 2026		33.28%	66.72%	0.00
31 Aug 2026		33.28%	66.72%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you